Difference between revisions of "MDAI"
From DMT-Nexus Wiki
(3 intermediate revisions by one user not shown) | |||
Line 7: | Line 7: | ||
* Nausea, headache, tiredness, depression, rise in blood pressure | * Nausea, headache, tiredness, depression, rise in blood pressure | ||
| | | | ||
− | * Mental addiction | + | * Mental addiction. WARNING: Some studies have shown that much of what is sold online as "MDAI" actually contains mephedrone or other similar drugs. |
| | | | ||
* Cardiovascular toxicity has not been tested. As of 2013, long-term studies on this substance have not been performed, so long term effects are still UNKNOWN! | * Cardiovascular toxicity has not been tested. As of 2013, long-term studies on this substance have not been performed, so long term effects are still UNKNOWN! | ||
Line 13: | Line 13: | ||
== Brief overview - What is MDAI? == | == Brief overview - What is MDAI? == | ||
− | 5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects | + | 5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects but, unlike similar drugs, it results in little to no stimulant effects. |
Latest revision as of 22:24, 19 December 2013
Brief overview - What is MDAI?
5,6-Methylenedioxy-2-aminoindane (MDAI) is a drug developed by David E. Nichols at Purdue University in the early 1990s. It is a highly selective serotonin releasing agent (SSRA). Like MDA and MDMA, it produces entactogenic effects but, unlike similar drugs, it results in little to no stimulant effects.